Natalia Morawiec

Ms. Natalia Morawiec

Medical University of Silesia, Katowice, Poland
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Medicina
Verified
Journal Article
Open access
PDF file
BABożena Adamczyk
Bożena Adamczyk
Karolina WęgrzynKarolina Węgrzyn
Karolina Węgrzyn
TWTomasz Wilczyński
Tomasz Wilczyński
Justyna MaciarzJustyna Maciarz
Justyna Maciarz
NMNatalia Morawiec
Natalia Morawiec
MAMonika Adamczyk-Sowa
Monika Adamczyk-Sowa
Epilepsy is a common neurological disorder characterized by chronic, unprovoked and recurrent seizures, which are the result of rapid and excessive bioelectric discharges in nerve cells. Neuroimaging is used to detect underlying structural abnormalities which may be associated with epilepsy. This paper reviews the most common abnormalities, such as hippocampal sclerosis, malformations of cortical development and vascular malformation, detected by neuroimaging in patients with epilepsy to help understand the correlation between these changes and the course, treatment and prognosis of epilepsy. Magnetic resonance imaging (MRI) reveals structural changes in the brain which are described in this review. Recent studies indicate the usefulness of additional imaging techniques. The use of fluorodeoxyglucose positron emission tomography (FDG-PET) improves surgical outcomes in MRI-negative cases of focal cortical dysplasia. Some techniques, such as quantitative image analysis, magnetic resonance spectroscopy (MRS), functional MRI (fMRI), diffusion tensor imaging (DTI) and fibre tract reconstruction, can detect small malformations—which means that some of the epilepsies can be treated surgically. Quantitative susceptibility mapping may become the method of choice in vascular malformations. Neuroimaging determines appropriate diagnosis and treatment and helps to predict prognosis.

25 June 2025 in Medicina
Verified
Journal Article
Open access
PDF file
NMNatalia Morawiec
Natalia Morawiec
BABożena Adamczyk
Bożena Adamczyk
ASAleksandra Spyra
Aleksandra Spyra
MHMikołaj Herba
Mikołaj Herba
SBSylwia Maria Boczek
Sylwia Maria Boczek
MAMonika Adamczyk-Sowa
Monika Adamczyk-Sowa
Background and Objectives: The Epstein-Barr virus (EBV) belongs to the gamma herpesviruses family. Evidence from the literature suggests that EBV initiates immune responses and the production of antibodies. Chronic or recurrent EBV infections may be associated with autoimmune diseases such as systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, multiple sclerosis, or inflammatory bowel diseases. This review aims to establish the role of EBV in the development and progression of autoimmune diseases. Materials and Methods: A literature search was conducted using PubMed, PMC, Google Scholar, and SCOPUS. Relevant studies, including meta-analyses, case-control studies, literature reviews, cross-sectional studies, and longitudinal studies, were identified through titles and abstracts screening for a comprehensive analysis. Results: Our study revealed a strong association between EBV infection and several autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. Epstein-Barr virus seropositivity was significantly higher in affected individuals. Elevated EBV-specific antibodies correlated with disease onset and severity. EBV DNA and latency proteins were detected in diseased tissues, alongside immune dysregulation and molecular mimicry mechanisms. Conclusions: Our findings highlight that EBV may be an important factor in autoimmune disease pathogenesis, contributing to immune activation and tissue damage. Further research is needed to explore EBV-targeted therapies and their potential in preventing or managing autoimmune diseases.

12 May 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
ACAgata Czarnowska
Agata Czarnowska
JTJoanna Tarasiuk
Joanna Tarasiuk
OZOlga Zajkowska
Olga Zajkowska
MWMarcin Wnuk
Marcin Wnuk
MMMonika Marona
Monika Marona
AKAlina Kułakowska
Alina Kułakowska
(1) Background: The present study aims to report the side effects of vaccination against coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) who were being treated with disease-modifying therapies (DMTs) in Poland. (2) Methods: The study included 2261 patients with MS who were being treated with DMTs, and who were vaccinated against COVID-19 in 16 Polish MS centers. The data collected were demographic information, specific MS characteristics, current DMTs, type of vaccine, side effects after vaccination, time of side-effect symptom onset and resolution, applied treatment, relapse occurrence, and incidence of COVID-19 after vaccination. The results were presented using maximum likelihood estimates of the odds ratio, t-test, Pearson’s chi-squared test, Fisher’s exact p, and logistic regression. The statistical analyses were performed using STATA 15 software. (3) Of the 2261 sampled patients, 1862 (82.4%) were vaccinated with nucleoside-modified messenger RNA (mRNA) vaccines. Mild symptoms after immunization, often after the first dose, were reported in 70.6% of individuals. Symptoms included arm pain (47.5% after the first dose and 38.7% after the second dose), fever/chills/flu-like symptoms (17.1% after the first dose and 20.5% after the second dose), and fatigue (10.3% after the first dose and 11.3% after the second dose). Only one individual presented with severe side effects (pro-thrombotic complications) after vaccination. None of the DMTs in the presented cohort were predisposed to the development of side effects. Nine patients (0.4%) had a SARS-CoV-2 infection confirmed despite vaccination. (4) Conclusions: Vaccination against SARS-CoV-2 is safe for people with MS who are being treated with DMTs. Most adverse events following vaccination are mild and the acute relapse incidence is low.

31 August 2021 in Neurologia i Neurochirurgia Polska
Verified
Journal Article
Closed access
PDF file
BABożena Adamczyk
Bożena Adamczyk
NMNatalia Morawiec
Natalia Morawiec
MAMonika Arendarczyk
Monika Arendarczyk
MBMonika Baran
Monika Baran
KWKrzysztof Wierzbicki
Krzysztof Wierzbicki
MAMonika Adamczyk-Sowa
Monika Adamczyk-Sowa
Introduction: The global pandemic of COVID-19 began in Wuhan, China in December 2019. Research into effective therapies has been conducted worldwide. Currently, there is no antiviral treatment and many patients develop a severe course of the disease, including severe respiratory failure. Due to similar pathomechanisms of inflammation in multiple sclerosis (MS) and COVID-19, immunomodulatory drugs that are registered for the treatment of MS are under study in the SARS-CoV-2 infection in clinical trials. Materials and methods: Using clinicaltrials.gov, we found information related to ongoing clinical studies on potential drugs for COVID-19 which are also used in MS therapy. The outcomes of several trials were published on pubmed.ncbi.nlm.nih.gov. Results: There were 18 clinical trials evaluating the effectiveness and safety of interferon-β, fingolimod, or leflunomide in COVID-19. Some trial outcomes available at pubmed.ncbi.nlm.nih.gov suggested an association of these drug treatments with improvements in signs and symptoms, and the disease course. Conclusion: The administration of immunomodulatory drugs in COVID-19 may result in potential beneficial effects probably associated with their anti-inflammatory and antiviral properties. Further research is warranted to confirm the long-term effects of immunomodulatory therapies in patients with COVID-19. Introduction: The global pandemic of COVID-19 began in Wuhan, China in December 2019. Research into effective therapies has been conducted worldwide. Currently, there is no antiviral treatment and many patients develop a severe course of the disease, including severe respiratory failure. Due to similar pathomechanisms of inflammation in multiple sclerosis (MS) and COVID-19, immunomodulatory drugs that are registered for the treatment of MS are under study in the SARS-CoV-2 infection in clinical trials. Materials and methods: Using clinicaltrials.gov, we found information related to ongoing clinical studies on potential drugs for COVID-19 which are also used in MS therapy. The outcomes of several trials were published on pubmed.ncbi.nlm.nih.gov. Results: There were 18 clinical trials evaluating the effectiveness and safety of interferon-β, fingolimod, or leflunomide in COVID-19. Some trial outcomes available at pubmed.ncbi.nlm.nih.gov suggested an association of these drug treatments with improvements in signs and symptoms, and the disease course. Conclusion: The administration of immunomodulatory drugs in COVID-19 may result in potential beneficial effects probably associated with their anti-inflammatory and antiviral properties. Further research is warranted to confirm the long-term effects of immunomodulatory therapies in patients with COVID-19.

15 September 2022 in Religions
Verified
Journal Article
Open access
PDF file
Marcin WnukMarcin Wnuk
Marcin Wnuk
Maciej WilskiMaciej Wilski
Maciej Wilski
MSMałgorzata Szcześniak
Małgorzata Szcześniak
HBHalina Bartosik-Psujek
Halina Bartosik-Psujek
KKKatarzyna Kapica-Topczewska
Katarzyna Kapica-Topczewska
APAndrzej Potemkowski
Andrzej Potemkowski
Religiosity and spirituality can be both beneficial and harmful to happiness. It depends on its operationalization and the measures of religiosity and sociodemographics used, together with cultural and psychosocial factors, still not comprehensively explored. This topic is especially important for religious-affiliated chronic patients such as those diagnosed with multiple sclerosis. Religion can deliver a sense of meaning, direction, and purpose in life and be an additional source of support to cope with the stress and limitations connected with the disease. The aim of the present study was to verify whether religiosity, directly and indirectly, through finding meaning in life, is related to one’s level of happiness and whether gender, the drinking of alcohol, financial status, and age are moderators in this relationship. In sum, 600 patients from Poland who suffered from multiple sclerosis were included in the study. Firstly, some gender differences were noticed. In women, religiosity was both directly and indirectly, through finding significance, positively related to happiness. Secondly, it was found that in women, the direct effect of age on happiness was generally negative but was positively affected by religiosity; however, among men, age was not correlated with happiness. In the group of women, religiosity and a lower propensity to drink alcohol in an interactive way explained happiness. Thirdly, both in men and women, financial status positively correlated with happiness, but in the group of wealthy men only, religiosity was negatively related to happiness. In conclusion, religion was found to show a positive correlation with the happiness of Roman Catholic multiple sclerosis patients from Poland. In this group of patients, religious involvement can be suggested and implemented as a factor positively related to happiness, with the one exception regarding wealthy men.

MSMałgorzata Szcześniak
Małgorzata Szcześniak
APAndrzej Potemkowski
Andrzej Potemkowski
WBWaldemar Brola
Waldemar Brola
ZKZdzisław Kroplewski
Zdzisław Kroplewski
RSRoman Szałachowski
Roman Szałachowski
MRMarcin Ratajczak
Marcin Ratajczak
Scientific achievements concerning the direct relation between personality traits and positive orientation among patients with multiple sclerosis do not explain the role of potential mediators. In fact, some researchers argue that the traits–positivity association is much more complex than it seems to be. For this reason, we made an attempt to analyze the indirect relationship between the above-mentioned variables, including meaning in life as a mediator. In total, 618 patients with MS took part in the study. The NEO Five-Factor Inventory, the Positive Orientation Scale, and the Meaning in Life Questionnaire were used. The results showed that positive orientation/the presence of meaning/searching for meaning correlated positively with extraversion, openness to experience, agreeableness, and conscientiousness, and were negatively associated with neuroticism. Moreover, meaning in life in both its dimensions acted as a mediator in 9 of 10 models. It can be assumed that a propensity to establish interpersonal relationships (extraversion), use active imagination (openness), inspire confidence among others (agreeableness), and take responsibility (conscientiousness) can have an impact on someone’s positive attitude toward oneself and the surrounding world (positive orientation) when people have meaning in life and when they are seeking it.